The high treatment costs are due to the length of survival achieved nowadays with combination endocrine therapy in the largest subset of BC, hormone-receptor-positive women, resulting in long periods on medication as well as individual per patient costs of novel therapies in HER2+ and triple-negative BC patients [93,94]. The gene discussed is NR4A1; the disease is breast cancer.